Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aussie Expert Suggests New Flu Vaccines Could Increase Danger

This article was originally published in PharmAsia News

Executive Summary

An Australian professor suggests vaccines that protect people against new types of influenza may actually increase the danger for those not considered at high risk

You may also be interested in...



EU Business Round-Up: Stada Enters Germany Top-5, Dr Wolff Takes Vagisan To Poland, Fidia And Sanova Strike Nasal Spray Deals

Acquiring six brands from GSK has propelled Stada into Germany's OTC top-5; Dr. Wolff has secured distribution for its Vagisan women's health brand in Poland; and Sanova and Fidia have added innovative nasal sprays to their respective portfolios.

European Medicines Agency Commits To Promoting Real-World Data

The European Medicines Agency commits to exploring real-world data as part of its new Regulatory Science Strategy to 2025.

Amgen Chooses To Settle In US Soliris IPR Tussle

Amgen’s burgeoning biosimilar presence continues to grow apace and now the company has eyes firmly on the US market for eculizumab after brokering a deal with originator Alexion. The biosimilars developer chose to settle on three of Alexion’s patents ahead of a trial later this year.

UsernamePublicRestriction

Register

LL1132033

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel